Ovarian Sertoli-Leydig cell tumors. A retrospective MITO study
Ovarian Sertoli-Leydig cell tumors. A retrospective MITO study
复制标题
DOI：
10.1016/j.ygyno.2012.03.024
复制
发表时间：
2012-06-01
影响因子：
4.7
通讯作者：
Mangili, Giorgia
中科院分区：
文献类型：
--
作者：
Sigismondi, Cristina;Gadducci, Angiolo;Mangili, Giorgia
Objective.目的探讨卵巢支持-间质细胞瘤（SLCTs）的临床病理特征及预后。对11个MITO中心的21例患者的资料进行回顾性分析。中位年龄为37岁（范围16-76岁）。FIGO分期：IA 17例（81%），IC 1例（4.8%），IIIB 1例（4.8%），IIIC 2例（9.5%）。5名患者（23.8%）患有G1肿瘤，10名（47.6%）患有G2，6名（28.6%）患有G3。11例患者行保留生育能力手术，10例患者行子宫切除术和双侧输卵管卵巢切除术; 5例患者接受辅助化疗（G2-3）。7例患者（33.3%）复发，中位复发时间为14个月。6例复发患者为G2-3期，1例为G1期。4例患者为IA期疾病，1例为IC期，2例为IIIC期。IA期患者未接受辅助化疗。2例患者盆腔复发，4例腹部复发（1例淋巴结受累），1例对侧卵巢和套管针入路复发。5例患者接受挽救性手术加化疗，1例仅接受挽救性化疗和1例姑息治疗。5名患者死于疾病，4名患者不是在MITO中心接受首次治疗的。C1期患者的5年总生存率为100%，G2-3期为77.8%。5年总生存率I期为92.3%，> I期为33.3%。1级SLCT患者无需辅助化疗预后良好。晚期或2-3级肿瘤患者似乎受益于术后化疗。(C)2012 Elsevier Inc. All rights reserved.
Objective. To evaluate clinicopathologic features and to investigate the outcome of patients with ovarian Sertoli-Leydig cell tumors (SLCTs).Methods. Data concerning 21 patients treated in 11 MITO centers were retrospectively reviewed.Results. Median age was 37 (range 16-76). FIGO stage was: 17 (81%) IA, 1(4.8%) IC, 1 (4.8%) IIIB and 2 (9.5%) IIIC. Five patients (23.8%) had G1 tumor, ten (47.6%) had G2, and six (28.6%) had G3. Fertility-sparing operation was performed in 11 patients, while hysterectomy with bilateral salpingo-oophorectomy was executed in 10 patients; five patients received adjuvant chemotherapy (G2-3). Seven patients (33.3%) relapsed with a median time to recurrence of 14 months. Six recurrent patients had G2-3 disease, while one had G1. Four patients had stage IA disease, one IC and 2 stage IIIC. Patients with stage IA disease did not receive adjuvant chemotherapy. Two patients had pelvic recurrence, 4 abdominal (one with lymph nodal involvement), one on the contralateral ovary and the trocar access. Five patients underwent salvage surgery plus chemotherapy, while one received only salvage chemotherapy and one palliation. Five patients died of disease, four had received first treatment not in a MITO center. 5 year overall survival was 100% for patients with Cl disease and 77.8% for G2-3. 5 year overall survival was 92.3% for stage I and 33.3% for stage > I.Conclusions. The prognosis of patients with grade 1 SLCT is excellent without adjuvant chemotherapy. Patients with advanced stage or grade 2-3 tumors appear to benefit from postoperative chemotherapy. (C) 2012 Elsevier Inc. All rights reserved.